Oxidative Demethylenation and Subsequent Glucuronidation Are the Major Metabolic Pathways of Berberine in Rats

被引:99
作者
Liu, Yitong [2 ]
Hao, Haiping [2 ]
Xie, Hongguang [3 ]
Lv, Hua [4 ]
Liu, Changxiao [1 ]
Wang, Guangji [2 ]
机构
[1] Tianjin Inst Pharmaceut Res, Res Ctr New Drug Evaluat, Natl Lab Pharmacodynam & Pharmacokinet, Tianjin, Peoples R China
[2] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
[3] Univ Calif San Francisco, Sch Pharm, Univ Calif Washington Ctr, Ctr Drug Dev Sci,Dept Pharmaceut Sci, Washington, DC USA
[4] PharmaResources Shanghai Co Ltd, Metab & Pharmacokinet, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
BBR; pharmacokinetics; metabolic clearance; microsomes; enzyme kinetics; CYPs; UGTs; HUMAN UDP-GLUCURONOSYLTRANSFERASES; IN-VITRO; LIVER-MICROSOMES; MAHONIA-AQUIFOLIUM; CYTOCHROME-P450; IDENTIFICATION; INVOLVEMENT; INHIBITION; ALKALOIDS; ISOFORMS;
D O I
10.1002/jps.21721
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Present study was designed to explore roles of metabolic clearance in the disposition of berberine (BBR) in rats, with a focus on oxidative metabolism and subsequent glucuronidation. Plasma from rats after intravenous administration of BBR was collected to identify and quantify BBR and its major metabolites. The major circulating metabolites of BBR were oxidative metabolites M1 (via demethylation) and M2 (via demethylenation) and their corresponding glucuronides, with M2-glucuronide approximately 24-fold higher than M1-glucuronide. Incubations with rat liver microsomes were conducted to examine formation kinetics of two oxidative metabolites-M1 and M2, and depletion kinetics of M1 and M2, leading to the formation of glucuronide conjugates. Efforts were also made to examine roles of key CYPs and UGTs isoforms responsible for BBR metabolism using known chemical inhibitors and/or substrates. In vitro, the formation of M1 and M2 were comparable and multiple CYP enzymes were involved. In contrast, the glucuronidation of M2 was much faster than that of M1. Inhibition studies using well-characterized UGT substrates suggested both M1 and M2 could be glucuronidated by UGT1A1 and UGT2B1 while M2 glucuronidation was favored by UGT1A1. In summary, oxidative demethylenation and the subsequent glucuronidation were the major metabolic pathways of BBR in rats. (C) 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:4391-4401, 2009
引用
收藏
页码:4391 / 4401
页数:11
相关论文
共 36 条
[1]   BERBERINE SULFATE - ANTIMICROBIAL ACTIVITY, BIOASSAY, AND MODE OF ACTION [J].
AMIN, AH ;
SUBBAIAH, TV ;
ABBASI, KM .
CANADIAN JOURNAL OF MICROBIOLOGY, 1969, 15 (09) :1067-&
[2]   Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK [J].
Cheng, Zhe ;
Pang, Tao ;
Gu, Min ;
Gao, An-Hui ;
Xie, Chuan-Ming ;
Li, Jing-Ya ;
Nan, Fa-Jun ;
Li, Jia .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2006, 1760 (11) :1682-1689
[3]   Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide [J].
D'Andrea, V ;
Pérez, LM ;
Pozzi, EJS .
LIFE SCIENCES, 2005, 77 (06) :683-692
[4]   The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole [J].
Elsherbiny, Marwa E. ;
El-Kadi, Ayman O. S. ;
Brocks, Dion R. .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2008, 11 (01) :146-159
[5]  
GUDIMA SO, 1994, MOL BIOL+, V28, P809
[6]   Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation [J].
Hao, Haiping ;
Wang, Guangji ;
Cui, Nan ;
Li, Jing ;
Xie, Lin ;
Ding, Zuoqi .
CURRENT DRUG METABOLISM, 2007, 8 (02) :137-149
[7]  
HONG JY, 1989, CANCER RES, V49, P2973
[8]  
Kettmann V, 2004, PHARMAZIE, V59, P548
[9]   Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response [J].
Kim, TS ;
Kang, BY ;
Cho, DH ;
Kim, SH .
IMMUNOLOGY, 2003, 109 (03) :407-414
[10]   Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins [J].
Kong, WJ ;
Wei, J ;
Abidi, P ;
Lin, MH ;
Inaba, S ;
Li, C ;
Wang, YL ;
Wang, ZZ ;
Si, SY ;
Pan, HN ;
Wang, SK ;
Wu, JD ;
Wang, Y ;
Li, ZR ;
Liu, JW ;
Jiang, JD .
NATURE MEDICINE, 2004, 10 (12) :1344-1351